After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Sanofi is to take on Boehringer Ingelheim's consumer health division in exchange for ... a good fit with its existing business in terms of products and geographies, giving it much increased ...

Procter & Gamble and Colgate-Palmolive are among the defendants in six new lawsuits targeting the sale of toothpaste and ...

The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

Fluoride helps prevent cavities when applied topically to the teeth, but when ingested can pose significant risks, even kill ...

Procter & Gamble, Colgate, Perrigo and Sanofi did not ... into believing these products are harmless to young children." The relationship between fluoride and human health has long been debated.

Other challenged products include Perrigo’s Firefly anti-cavity rinse and Sanofi’s ACT Kids rinse. The proposed class actions cite warnings from US health regulators that fluoride-based ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past ...

Banks are pitching around €1 billion ($1.05 billion) in debt packages to back a potential buyout of Karo Healthcare, according to people familiar with the matter.